GUTS
FRACTYL HEALTH, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.38
−10.97%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -4.9%
- EBIT
- +14.0%
- EPS
- -61.0%
- Free cash flow
- -0.1%
- Operating cash flow
- -1.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +51.1%
- EPS
- +63.6%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- -3.5%
- Net income
- —
- EPS
- +43.2%
- Free cash flow
- -35.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026